Home Brain Tumors SISAQOL consortium – first international standards for quality of life measurement in...

SISAQOL consortium – first international standards for quality of life measurement in cancer clinical trials published in The Lancet Oncology

Cancer patients’ quality of life is becoming an increasingly important outcome in clinical trials. Known as patient-reported outcomes (PROs), factors such as symptoms, function, and other health-related quality-of-life aspects, provide essential information about measuring the clinical benefit of any given therapy. There is however no consensus on the optimal methods to  analyse PROs in cancer clinical trials.

Members of the SISAQOL consortium

A policy review paper, published in the February 2020 edition of The Lancet Oncology, has for the first time established International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials. A diverse panel of researchers and statisticians, key individuals from various international oncologic and medical societies, advisory and regulatory bodies, academic societies,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments